Ketamine as an NMDA-modulating therapy in bipolar disorder
Rationale and evidence
Bibliographic Data
| ID | 15525960 |
|---|---|
| Authors | Robert Queissner (0000-0001-6632-0902, Medical University of Graz, corresponding author), F Fellendorf (Medical University of Graz), E Z Reininghaus (Medical University of Graz) |
| Year | 2026 |
| Volume | 17 |
| Pages | 1777402-1777402 |
| Publication date | 2026-03-04 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2026.1777402 |
| PMID | 41858652 |
| OpenAlex | W7133505539 |
| Language | EN |
| References cited | 12 |
Ketamine and esketamine represent mechanistically novel and clinically effective treatments for bipolar depression. Their rapid antidepressant action and low switch liability distinguish them from traditional antidepressants. Esketamine, with its favorable tolerability and intranasal administration, offers a promising adjunctive option for treatment-resistant bipolar depression. Long-term data are warranted to optimize maintenance strategies and confirm sustained safety and efficacy
Antidepressant · Bipolar disorder · Depression (economics · Ketamine · Mania · Mood · Tolerability · Treatment-resistant depression · Bipolar Disorder and Treatment · Treatment of Major Depression · Tryptophan and brain disorders
| Citation velocity | historical |
|---|---|
| Highly cited | No |